Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of subcutaneous amlitelimab in adults with moderate-to-severe asthma
2023-503385-24-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2 trial of amlitelimab in asthma (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of participants with treatment-emergent adverse events. Started Mar 2024; status: completed.
02
Drugs
amlitelimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-503385-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503385-24-00.